Bio-Rad Laboratories - BIO Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIO shares.
View BIO analyst ratings or view top-rated stocks.

4 brokerages have issued 12 month price objectives for Bio-Rad Laboratories' shares. Their BIO share price forecasts range from $579.00 to $700.00. On average, they expect the company's share price to reach $664.75 in the next year. This suggests a possible upside of 39.2% from the stock's current price.
View analysts price targets for BIO or view top-rated stocks among Wall Street analysts.

Bio-Rad Laboratories' stock was trading at $420.49 on January 1st, 2023. Since then, BIO shares have increased by 13.6% and is now trading at $477.55.
View the best growth stocks for 2023 here.

Bio-Rad Laboratories saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 362,400 shares, an increase of 29.9% from the February 28th total of 279,000 shares. Based on an average trading volume of 167,300 shares, the days-to-cover ratio is currently 2.2 days. Currently, 1.7% of the shares of the stock are sold short.
View Bio-Rad Laboratories' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our BIO earnings forecast.

Bio-Rad Laboratories, Inc. (NYSE:BIO) released its earnings results on Thursday, February, 16th. The medical research company reported $3.31 EPS for the quarter, missing analysts' consensus estimates of $3.45 by $0.14. The medical research company had revenue of $730.29 million for the quarter, compared to analyst estimates of $741.01 million. Bio-Rad Laboratories had a positive trailing twelve-month return on equity of 4.59% and a negative net margin of 129.66%. The firm's quarterly revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.21 earnings per share.
Read the conference call transcript.

ETFs with the largest weight of Bio-Rad Laboratories (NYSE:BIO) stock in their portfolio include Putnam BioRevolution ETF (SYNB), ETFMG Treatments Testing and Advancements ETF (GERM), Harbor Health Care ETF (MEDI), Principal Healthcare Innovators ETF (BTEC), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Putnam Sustainable Future ETF (PFUT), First Trust Indxx Medical Devices ETF (MDEV) and Invesco S&P 500 Equal Weight Health Care ETF (RYH).

Bio-Rad Laboratories issued an update on its FY 2023 earnings guidance on Monday, February, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.97 billion-$3.00 billion, compared to the consensus revenue estimate of $2.91 billion.

325 employees have rated Bio-Rad Laboratories Chief Executive Officer Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

Bio-Rad Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional investors include Veritas Asset Management LLP (3.86%), Brown Advisory Inc. (2.75%), Alliancebernstein L.P. (1.61%), Geode Capital Management LLC (1.46%), Bank of America Corp DE (1.37%) and AustralianSuper Pty Ltd (1.09%). Insiders that own company stock include Ajit Ramalingam, Annette Tumolo, Giovanni Magni, Ilan Daskal, Michael Crowley, Ronald W Hutton, Timothy S Ernst and Timothy S Ernst.
View institutional ownership trends.

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIO stock can currently be purchased for approximately $477.55.

Bio-Rad Laboratories (NYSE:BIO) has a market capitalization of $14.14 billion and generates $2.80 billion in revenue each year. The medical research company earns $-3,627,530,000.00 in net income (profit) each year or ($121.43) on an earnings per share basis.

The company employs 8,200 workers across the globe.

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The official website for the company is www.bio-rad.com. The medical research company can be reached via phone at (510) 724-7000, via email at investor_relations@bio-rad.com, or via fax at 510-741-5817.